Le Lézard
Classified in: Health
Subject: FDA

Acella Pharmaceuticals, LLC, announces approval of generic to Vituz® Oral Solution

ATLANTA, July 27, 2017 /PRNewswire/ -- Acella Pharmaceuticals, LLC, a leading U.S. developer of specialty pharmaceuticals across several therapeutic categories, recently announced the Food and Drug Administration's approval of the Company's abbreviated new drug application (ANDA) for a Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution 5 mg/4 mg per 5 mL as a bioequivalent product to VITUZ® Oral Solution. This approval continues Acella Pharmaceuticals' diverse portfolio of products and the commitment to provide effective and affordable health care solutions for its broad and growing base of customers.

Acella Pharmaceuticals, LLC

This combination medicine is indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. The incidence of the common cold exceeds one billion cases in the United States each year. A majority of the population is likely to have more colds than any other type of illness. Colds can occur at any time of the year, but they are most common in the winter or rainy seasons. 1-3

"Acella continues to actualize new product launch opportunities that align with our strategic mission to provide optimal healthcare support for the medical community and their patient population," said Harold A. Deas, Jr., CEO for Acella Pharmaceuticals.

"Access to affordable and effective solutions for common illnesses is critical in our current healthcare environment," said Allen Fields, Acella's Senior VP, Clinical and Regulatory Affairs, Head of Research and Development. "Our team at Acella will continue to focus on product opportunities to positively impact the greatest healthcare needs in our society."

About Acella Pharmaceuticals, LLC

Acella develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications.  Acella specializes in identifying and bringing to market quality, affordable products to customers and patients.  For additional information please contact Acella at 678-325-5189, or visit www.acellapharma.com.

An Abbreviated New Drug Application (ANDA) contains data which, when submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low-cost alternative to the American public.

A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.  All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).

1 Turner RB. The common cold. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 369.
2 Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am Fam Physician. 2012;86(2):153-159.
3 Singh M, Das RR. Zinc for the common cold. Cochrane Database of Systematic Reviews. 2011, Issue 2. Art. No.: CD001364.

SOURCE Acella Pharmaceuticals, LLC

These press releases may also interest you

at 03:00
NEW HAVEN, Conn., Oct. 24, 2017 /PRNewswire/ -- (NYSE: BHVN) Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the "Company") and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug...

at 03:00
NEW YORK, Oct. 24, 2017 /PRNewswire-iReach/ -- On October 28th, the Endometriosis Foundation of America (endofound.org) is bringing leading medical experts together to examine the relationship between endometriosis and breast and ovarian cancers.  ...

at 02:28
STOCKHOLM, Oct. 24, 2017 /PRNewswire/ --Essity, a leading hygiene and health company, has been recognized as a global leader for its action on water and forests and received the highest score from CDP, an international not-for-profit charity that...

at 02:00
DURHAM, N.C., Oct. 24, 2017 /PRNewswire/ -- A newly released modeling study conducted by The Tufts Center for the Study of Drug Development (CSDD) finds that sponsors who employ single-source outsourcing partners, versus a multivendor development and...

at 02:00
ST. PETERSBURG, Russia, Oct. 24, 2017 /PRNewswire/ -- Many Christian doctors from across the world came together, presented and shared various divine healing cases, which had occurred by the power of God, at the 14th WCDN (World Christian Doctors...

at 00:32
SIMI VALLEY, Calif., Oct. 24, 2017 /PRNewswire/ -- EazyHold has received its patent for the first silicone grip aids. Designed for use at home, hospitals and schools, it's one of the simplest ways to solve the universal problem of poor hand function...

News published on 27 july 2017 at 09:10 and distributed by: